Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma

被引:25
作者
Boone, Brian A. [1 ]
Zeh, Herbert J. [1 ]
Mock, Brady K. [2 ]
Johnson, Paul J. [2 ]
Dvorchik, Igor [1 ]
Lee, Ken [1 ]
Moser, A. James [3 ]
Bartlett, David L. [1 ]
Marsh, J. Wallis [1 ]
机构
[1] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[3] BIDMC, Dept Surg, Boston, MA USA
基金
美国国家卫生研究院;
关键词
PANCREATIC DUCTAL ADENOCARCINOMA; LONG-TERM SURVIVAL; CURATIVE RESECTION; REMNANT PANCREAS; CANCER; FOLFIRINOX; GEMCITABINE; CARCINOMA; SURGERY; CHEMOTHERAPY;
D O I
10.1111/hpb.12119
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundThe majority of patients with periampullary cancer develop local or metastatic recurrence despite successful negative margin resection. Unfortunately, there are no established therapeutic strategies for managing these patients. The literature on the surgical resection of recurrent disease is limited. MethodsThis is a retrospective study evaluating patients who underwent reoperative resection of recurrent periampullary cancer at a single institution between 1990 and 2011. Perioperative outcomes were compared with those of the original primary resections for patients with local recurrence. Kaplan-Meier curves were used to evaluate survival. ResultsTwenty-two patients underwent reoperative resection following the successful primary resection of periampullary cancers. Median survival from the time of reoperation was 28.1 months. A greater survival benefit was seen in patients undergoing reoperative resection with >15 months between the primary resection and recurrence (40.6 months versus 8.2 months; P < 0.05). Complication rates were lower after reoperative resection compared with the primary resection (20% versus 70%). Perioperative characteristics including operative time, estimated blood loss and hospital stay were similar in both the primary and reoperation procedures. ConclusionsSurgical resection of periampullary cancer recurrence is feasible, safe and may offer survival benefits in comparison with alternative treatment modalities. Reoperative resection should be considered, especially in patients in whom the time to recurrence is lengthy.
引用
收藏
页码:197 / 203
页数:7
相关论文
共 36 条
[1]   Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: A north central cancer treatment group phase II trial [J].
Alberts, SR ;
Schroeder, M ;
Erlichman, C ;
Steen, PD ;
Foster, NR ;
Moore, DF ;
Rowland, KM ;
Nair, S ;
Tschetter, LK ;
Fitch, TR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) :4944-4950
[2]   Pulmonary Resection for Isolated Pancreatic Adenocarcinoma Metastasis: an Analysis of Outcomes and Survival [J].
Arnaoutakis, George J. ;
Rangachari, Deepa ;
Laheru, Daniel A. ;
Iacobuzio-Donahue, Chris A. ;
Hruban, Ralph H. ;
Herman, Joseph M. ;
Edil, Barish H. ;
Pawlik, Timothy M. ;
Schulick, Richard D. ;
Cameron, John L. ;
Meneshian, Avedis ;
Yang, Stephen C. ;
Wolfgang, Christopher L. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2011, 15 (09) :1611-1617
[3]   5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma [J].
Assaf, Elias ;
Verlinde-Carvalho, Muriel ;
Delbaldo, Catherine ;
Grenier, Julien ;
Sellam, Zineb ;
Pouessel, Damien ;
Bouaita, Linda ;
Baumgaertner, Isabelle ;
Sobhani, Iradj ;
Tayar, Claude ;
Paul, Muriel ;
Culine, Stephane .
ONCOLOGY, 2011, 80 (5-6) :301-306
[4]  
Cameron JL, 2006, ANN SURG, V244, P10, DOI 10.1097/01.sla.0000217673.04165.ea
[5]   The Clavien-Dindo Classification of Surgical Complications Five-Year Experience [J].
Clavien, Pierre A. ;
Barkun, Jeffrey ;
de Oliveira, Michelle L. ;
Vauthey, Jean Nicolas ;
Dindo, Daniel ;
Schulick, Richard D. ;
de Santibanes, Eduardo ;
Pekolj, Juan ;
Slankamenac, Ksenija ;
Bassi, Claudio ;
Graf, Rolf ;
Vonlanthen, Rene ;
Padbury, Robert ;
Cameron, John L. ;
Makuuchi, Masatoshi .
ANNALS OF SURGERY, 2009, 250 (02) :187-196
[6]   Long-term survival after curative resection for pancreatic ductal adenocarcinoma - Clinicopathologic analysis of 5-year survivors [J].
Conlon, KC ;
Klimstra, DS ;
Brennan, MF .
ANNALS OF SURGERY, 1996, 223 (03) :273-279
[7]   Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results [J].
Conroy, Thierry ;
Mitry, Emmanuel .
BULLETIN DU CANCER, 2011, 98 (12) :1439-1446
[8]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[9]  
D'Amato Alberto, 2002, Chir Ital, V54, P539
[10]   FOLFIRINOX: A Great Leap Forward, but for Whom? [J].
dos Santos, Lucas Vieira ;
de Andrade, Diocesio Pinto ;
Lima, Joao Paulo .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (01) :114-115